TW202014412A - 賽度替尼(cerdulatinib)之固體型式 - Google Patents

賽度替尼(cerdulatinib)之固體型式 Download PDF

Info

Publication number
TW202014412A
TW202014412A TW108115465A TW108115465A TW202014412A TW 202014412 A TW202014412 A TW 202014412A TW 108115465 A TW108115465 A TW 108115465A TW 108115465 A TW108115465 A TW 108115465A TW 202014412 A TW202014412 A TW 202014412A
Authority
TW
Taiwan
Prior art keywords
compound
salt
ray powder
diffraction pattern
powder diffraction
Prior art date
Application number
TW108115465A
Other languages
English (en)
Chinese (zh)
Inventor
安傑禮 潘迪
朱利安 史考特 諾森
菲利浦 佛南德斯
英 陳
躍列 盧
薩米 卡拉波爾尼
葛斯 柯德夏
Original Assignee
美商普托拉製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商普托拉製藥有限公司 filed Critical 美商普托拉製藥有限公司
Publication of TW202014412A publication Critical patent/TW202014412A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW108115465A 2018-05-04 2019-05-03 賽度替尼(cerdulatinib)之固體型式 TW202014412A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862667226P 2018-05-04 2018-05-04
US62/667,226 2018-05-04

Publications (1)

Publication Number Publication Date
TW202014412A true TW202014412A (zh) 2020-04-16

Family

ID=66641481

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108115465A TW202014412A (zh) 2018-05-04 2019-05-03 賽度替尼(cerdulatinib)之固體型式

Country Status (5)

Country Link
US (2) US10865198B2 (enExample)
EP (1) EP3788035B1 (enExample)
JP (1) JP7324778B2 (enExample)
TW (1) TW202014412A (enExample)
WO (1) WO2019213606A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736895B2 (en) 2015-12-04 2020-08-11 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
WO2019213606A2 (en) * 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
TWI805751B (zh) * 2018-05-04 2023-06-21 美商普托拉製藥有限公司 賽度替尼(cerdulatinib)之合成

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255756A (ja) 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
WO2003037352A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1518855B1 (en) 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
HRP20161310T1 (hr) 2008-04-16 2016-12-02 Portola Pharmaceuticals, Inc. 2,6-diamino-pirimidin-5-il-karboksamidi kao inhibitori syk ili jak kinaza
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
WO2010138588A2 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20120157500A1 (en) 2009-08-24 2012-06-21 Weikang Tao Jak inhibition blocks rna interference associated toxicities
EP2507227B1 (en) 2009-12-01 2014-10-08 Rigel Pharmaceuticals, Inc. Tetrazolones as protein kinase c inhibitors and uses thereof
US9357229B2 (en) 2010-07-28 2016-05-31 Qualcomm Incorporated Coding motion vectors in video coding
EP2621489A1 (en) 2010-09-30 2013-08-07 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
TW201427664A (zh) 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
JP7258462B2 (ja) 2015-05-29 2023-04-17 ポートラ ファーマシューティカルズ， エルエルシー Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
US10736895B2 (en) 2015-12-04 2020-08-11 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
CA3098012A1 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Methods for treating lymphoma
TWI805751B (zh) 2018-05-04 2023-06-21 美商普托拉製藥有限公司 賽度替尼(cerdulatinib)之合成
WO2019213606A2 (en) * 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib

Also Published As

Publication number Publication date
JP7324778B2 (ja) 2023-08-10
EP3788035A2 (en) 2021-03-10
WO2019213606A2 (en) 2019-11-07
US20210130330A1 (en) 2021-05-06
WO2019213606A3 (en) 2019-12-05
US10865198B2 (en) 2020-12-15
US11713309B2 (en) 2023-08-01
US20200031804A1 (en) 2020-01-30
JP2021523120A (ja) 2021-09-02
EP3788035B1 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
AU2018201896B2 (en) Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
JP6530792B2 (ja) Ｓｙｋ阻害剤
EP3027618B1 (en) Polymorph of syk inhibitors
CN110636884A (zh) (S)-2-(((S)-(((2R,3S,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4-二羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)氨基)丙酸-2-乙基丁基酯的结晶形式
JP2026001041A (ja) ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態
US11713309B2 (en) Solid forms of Cerdulatinib
JP2023536892A (ja) Ｊａｋ阻害剤化合物及びその使用
KR20140040671A (ko) 아프레피탄트 l-프롤린 조성물 및 공결정
JP2019509306A (ja) Ｊａｋ関連疾患の治療又は予防に用いる薬物の塩酸塩の結晶形及びその製造方法
US12122781B2 (en) Hydrates of polymorphs of 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-a]pyrazin-8-amine bis-mesylate as Syk inhibitors
CN119677746A (zh) Jak抑制剂的固体形式和其制备方法
HK1224671A1 (en) Polymorph of syk inhibitors
HK1224671B (en) Polymorph of syk inhibitors
HK1205430B (en) Salts of an epidermal growth factor receptor kinase inhibitor